IDRA will be presenting at the RBC Capital Markets' Global Healthcare Conference on Tuesday the 25th at 8:00 a.m. IDRA stock had a solid week gaining +36%, and has broke above prior resistance on above average volume.
Bottom Line: IDRA has almost doubled from the point we purchased the stock in the low three area. The company plans to disclose their phase 2 psoriasis trial results by the end of the first quarter which could be a stock moving event. We continue to hold shares of IDRA.
Contact: portfoliomgt1@gmail.com
Contact: portfoliomgt1@gmail.com
No comments:
Post a Comment